ABST& cr Vol. 38, No.5, 1995 Printed ill U.S.A.
HLA class II-deficient combined immunodeficiency (CID) is an inherited disease characterized by a total lack of HLA class II gene expression, due to a regulatory defect affecting these genes. In the family investigated the disease phenotype occurs parallel to an abnormal structural feature of the C023 antigen. We sequenced parts of the FCER2 gene coding for C023 and found a restriction fragment length polymorphism (RFLP) that cosegregates with the disease. Analysis of recombinant haplotypcs by microsatcllites mapping to the chromosomal region 19p13.3 suggests that the disease locus maps between FCER2 and the microsatellite marker 0 19S424, probably close to 01 9S216 and In clas s II-deficient cm the HLA class II genes are not transcribed , and expression of HLA class I antigens on the cell surface is also reduced (1) . The clini cal consequences are hypo-or aga mmaglobulinemia and imp aired ce ll-media ted immunity result ing in repe ated, severe infections and intr actable diarrhea with dystrophy cau sed by malab sorption (2) . Currently, the only cur ative therap y is bone marrow transpl antation, whereas under sy mptomatica l therap y most pati en ts die betw een the age of 6 mo and 5 y (3) .
The disease is inherited as an auto som al recessive trait wi th a high degree of consanguinity. Although none of the patients expresses HLA class II mRNA, the genetic defect does not segregate w ith the HLA complex. Hence, these observations suggest a defect in class II reg ulatory ge nes which are unlinked to the major histo compatibil ity complex (4) enco ding, for exa mple, cla ss II promoter-binding proteins (5).
HLA 
METHODS
General. HLA class II antigens were determined by fluorescence-activated cell cytometry. DNA and RNA were isolated by standard procedures (12) from cells of both parents, three healthy children, two of the affected children, and a chorionic villi sample and fetal blood of an umbilical cord puncture from the pregnant mother.
cDNA was synthesized and amplified using the GENE Amp RNA PCR Kit (Perkin-Elmer, Norwalk, CT) according to the manufacturer's protocol. PCR products were sequenced directly with the Cycle Sequencing Kit (Perkin-Elmer). SSCP analysis was done as described previously (13).
Analysis ofthe FCER2 locus. Oligonucleotide primers used are listed in Table 1 . The determined RFLP were tested for all family members by PCR amplification using the primers CD23-1 up and CD23-1 down for BstNI or CD23-3 up and CD23-4 down for Hpall RFLP. Amplification reactions contained 100 ng of genomic DNA and 200 nM of each oligonucleotide primer in a 50-fl,L reaction volume. The reactions were run for 35 cycles, 1 min each at 94, 60, and n°c. PCR products were digested overnight with BstNI or Hpall restriction endonuclease, separated on a 15% polyacrylamide gel (160 X 140 x 0.75 mm), and detected by silver staining.
Microsatellite analysis. Genomic DNA was amplified with the highly polymorphic microsatellite markers D19S247 (14), D19S209 (15) 
RESULTS
In the consanguineous family studied (parents are cousins), two girls and one boy were affected by MHC class II deficiency. Three out of six siblings are healthy (two girls and one boy).
The affected son was born healthy and of normal weight without any problems. After the neonatal period he developed In the first affected girl the same clinical problems occurred. Agammaglobulinemi a and immunologic findings led, as in the affected brother, to the diagnosis of MHC class II deficiency. Bone marrow transplantati on was planned and performed. She died during a severe sepsis 1 wk after haploidentical bone marrow transplantation in the 5th y of life.
MHC class II deficiency could be diagnosed by FACScan analysis in the second affected girl immediately after birth, before clinical symptoms occurred. The immunologic findings showed a complete lack of HLA class II molecule expression on B lymphocytes and activated T lymphocytes and the absence of serum immunoglobulins, as well as no in vitro responses to specific antigens. Haploidentical bone marrow transplantation was performed at the age of 5 mo. The father served as donor. After transplantation a chimeric pattern of MHC class II-negative and MHC class II-positive cells was present in the peripheral blood of the child. Delayed hypersensitivity skin tests became positive for tetanus, and diphtheria antigen as well as tetanus antigen-induced lymphocyte proliferation showed normal values. Ig production remained negative and IgG was given further on. Despite the improved cellular immunity gastrointestinal symptoms (diarrhea, malabsorption) persisted. At last the girl died during a severe septic infection with different Gram-negative rods and Candida albicans .
We isolated DNA and RNA from cells of both parents, three healthy children (C1-C3), two of the affected children (C4 and C5), and a chorionic villi sample and fetal blood of an umbilical cord puncture from the pregnant mother (C6) (Fig. 1a) . Cells of C6 showed normal expression of HLA class II antigens.
To analyze the nature of the aberrant Ti n epitope on CD23, we amplified parts of the CD23 cDNA by PCR using primers that were deduced from the published sequence (20, 21) . After restriction enzyme digestion to yield fragments smaller than 300 bp, the products were examined by SSCP analysis. Fragments showing heterozygosity in the parents were further examined by direct sequencing. We found two transitions, the first being located in exon 4 causing a Arg 62~T rp exchange and creating a new BstNI restriction site. The second point mutation, located in exon 9, causes an amino acid exchange Arg 18 8~G In (Fig. I c) and, concurrently, the destruction of a Hpall restriction site. We analyzed both RFLPs for cosegregation with the disease phenotype and found that the Hpall RFLP cosegregates with the disease in the reported family (Fig. 1b) , with the exception of child C6. In contrast, the BstNI RFLP segregates independently of the disease . Moreover, it Hp all 4 6 1 6 2 also appeared in the completely unrelated EBV-transformed cell line H2LCL.
We then analyzed several highly polymorphic microsatellite markers mapping to the 19p13.3 region, as shown in Fig 2a. This map is based on the marker distances given in Gyapay et al. (16) , therefore the locati on s of mark ers 01 9S1 77 , 01 9S247, and UT487 are given as ranges. Of the 11 primer pairs used, the marker LIPE (19) was unsuitable due to homozygosity exhibited by both parents. The segregation patterns of the other markers fall into four classes. An example of each of these is given in Fig 2a. Assuming single crossing overs as the most likely events, one crossing over between markers 0195424 and 019S216 in the mother, and one between 0 19S177 and UT486 in the father can be postulated to create the two haplotypes observed in CG. Most likely, another crossing over between 019S413 and 019S221 has occurred in one of the father's ancestors. From these results an order for the markers analyzed can be deduced (Fig. 2b) , placing FCER2 between 019S221 and 0 195216. Furthermore, the disease locus should reside telomeric of the marker UT486. On the other hand, it is centromeric of 0 195424 and 0 195209 because the healthy child C3 is homozygous for 019S424 and other more telomeric markers due to a maternal crossing over. The health y child C6 is heterozygous for 01 9S216 and 0 19S406 due to paternal crossing over and has the same allele constellation as his father. These results indicate that the disease locus may be located between UT486 and 019S424.
DISCUSSION
Starting with our working hypothesis that the aberrant T01 reactivity has a molecul ar basis in the FCER2 gene, we de- These findings can be explained by the analysis of several highly informative microsatellite markers, which show that a crossing over in 19p in the mother and in the father occurred. Therefore, in the case of C6, D19S216, D19S406, and D19S177 did not show the allele constellation expected for a diseased individual, indicating that this region is well separated from FCER2. Although the family investigated is small, a positive LOD score just above 1 for linkage between the disease locus and the markers D19S216 and D19S177 is obtained.
The presented results might offer the possibility of an earlier prenatal diagnosis for a subgroup of patients with HLA class II-deficient CID. Previously, direct determination of HLA class II antigen expression was possible only at about wk 20 (22) , but the characterization of two highly polymorphic DNA markers would allow the analysis of chorionic villi samples already in the 7th wk of pregnancy. However, it is clearly essential to investigate more families with this genetically heterogeneous inherited disorder to assess the true value of D19S177 and D19S216 in HLA class II-deficient cm. Cl DI9S20 'I D19S424 -a tected a HpaII RFLP in this gene that cosegregates with the disease phenotype. However, the mutated FC E receptor itself cannot give rise to the disease because class II-deficient CID patients, unrelated to the members of our family, did not exhibit FCER2 mutations. Cells from a further affected child were also unreactive with TUl, comparable to family members C4 and C5, but these cells were not available for this study. An exception of this was represented by child C6. The DNA analyzed was obtained from chorionic villi samples of a pregnancy existing at the time of the investigation. Analysis of the HpaII RFLP indicated homozygosity for the FCER2 mutation so that it was initially assumed that the child would exhibit the [) 1~IS~{i
